Role of Fenofibrate in Indirect Neonatal Hyperbilirubinemia: a Randomized Control Trial

• Status: Not yet recruiting
• Trial end date: 2022-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Fenofibrate accelerates bilirubin conjugation and excretion, decreasing the side effects of prolonged unconjugated hyperbilirubinemia in neonates. It also reduces the duration of phototherapy and thus the duration of stay in the hospital. This research is carried out to improve standard protocol for the management of neonatal hyperbilirubinemia in the local settings.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shaheed Zulfiqar Ali Bhutto Medical University
• Treatments: Fenofibrate

Criteria

INCLUSION CRITERIA:

• Gestational age ≥ 35 weeks

• Birth weight ≥ 2 kg

• Age: 2-7 days of life

• Total serum bilirubin level ≥15mg/dl and ≤20 mg/dl

EXCLUSION CRITERIA:

• Neonates with total bilirubin >20mg/dl

• Conjugated bilirubin level greater than 15% of total serum bilirubin

• Maternal hyperbilirubinemia (on medical record)

• Babies with congenital anomalies (on clinical examination)

• Those not consenting to participate in the study